1468P POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

T Golan,P Hammel,M Reni,E Van Cutsem,T Macarulla Mercade,M.J Hall,J.O Park,D Hochhauser,D Arnold,D-Y Oh,A Reinacher-Schick,G Tortora,H Algül,E.M O'Reilly,S Bordia,D Mcguinness,K.Y Cui,G Locker,H Kindler

doi:10.1016/j.annonc.2021.08.796

Abstract

In the phase III POLO trial (NCT02184195), progression-free survival was significantly prolonged on maintenance olaparib (O) relative to placebo (P) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer whose disease had not progressed after ≥ 16 weeks of first-line platinum-based chemotherapy. Here, we present subsequent therapies received after discontinuation of study treatment.

Full Text